131 related articles for article (PubMed ID: 24583874)
1. mTORC2 dictates Warburg effect and drug resistance.
Masui K; Cavenee WK; Mischel PS
Cell Cycle; 2014; 13(7):1053-4. PubMed ID: 24583874
[No Abstract] [Full Text] [Related]
2. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.
Masui K; Tanaka K; Akhavan D; Babic I; Gini B; Matsutani T; Iwanami A; Liu F; Villa GR; Gu Y; Campos C; Zhu S; Yang H; Yong WH; Cloughesy TF; Mellinghoff IK; Cavenee WK; Shaw RJ; Mischel PS
Cell Metab; 2013 Nov; 18(5):726-39. PubMed ID: 24140020
[TBL] [Abstract][Full Text] [Related]
3. mTORC2 in the center of cancer metabolic reprogramming.
Masui K; Cavenee WK; Mischel PS
Trends Endocrinol Metab; 2014 Jul; 25(7):364-73. PubMed ID: 24856037
[TBL] [Abstract][Full Text] [Related]
4. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment.
Masui K; Cavenee WK; Mischel PS
Brain Pathol; 2015 Nov; 25(6):755-9. PubMed ID: 26526943
[TBL] [Abstract][Full Text] [Related]
5. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c.
Hagiwara A; Cornu M; Cybulski N; Polak P; Betz C; Trapani F; Terracciano L; Heim MH; Rüegg MA; Hall MN
Cell Metab; 2012 May; 15(5):725-38. PubMed ID: 22521878
[TBL] [Abstract][Full Text] [Related]
6. Hepatic FOXO1 Target Genes Are Co-regulated by Thyroid Hormone via RICTOR Protein Deacetylation and MTORC2-AKT Protein Inhibition.
Singh BK; Sinha RA; Zhou J; Tripathi M; Ohba K; Wang ME; Astapova I; Ghosh S; Hollenberg AN; Gauthier K; Yen PM
J Biol Chem; 2016 Jan; 291(1):198-214. PubMed ID: 26453307
[TBL] [Abstract][Full Text] [Related]
7. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis.
Wei J; Long L; Yang K; Guy C; Shrestha S; Chen Z; Wu C; Vogel P; Neale G; Green DR; Chi H
Nat Immunol; 2016 Mar; 17(3):277-85. PubMed ID: 26808230
[TBL] [Abstract][Full Text] [Related]
8. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
Masui K; Tanaka K; Ikegami S; Villa GR; Yang H; Yong WH; Cloughesy TF; Yamagata K; Arai N; Cavenee WK; Mischel PS
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9406-11. PubMed ID: 26170313
[TBL] [Abstract][Full Text] [Related]
9. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
10. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors.
Lee D; Sykes SM; Kalaitzidis D; Lane AA; Kfoury Y; Raaijmakers MH; Wang YH; Armstrong SA; Scadden DT
Stem Cell Reports; 2014 Nov; 3(5):832-40. PubMed ID: 25418727
[TBL] [Abstract][Full Text] [Related]
11. The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer.
Zheng G; Jia X; Peng C; Deng Y; Yin J; Zhang Z; Li N; Deng M; Liu X; Liu H; Lu M; Wang C; Gu Y; He Z
Oncotarget; 2015 Mar; 6(9):6931-43. PubMed ID: 25749387
[TBL] [Abstract][Full Text] [Related]
12. Insulin-Dependent Regulation of mTORC2-Akt-FoxO Suppresses TLR4 Signaling in Human Leukocytes: Relevance to Type 2 Diabetes.
Zhang Z; Amorosa LF; Coyle SM; Macor MA; Birnbaum MJ; Lee LY; Haimovich B
Diabetes; 2016 Aug; 65(8):2224-34. PubMed ID: 27207509
[TBL] [Abstract][Full Text] [Related]
13. Leukemia propagating cells Akt up.
Gutierrez A; Roderick JE; Kelliher MA
Cancer Cell; 2014 Mar; 25(3):263-5. PubMed ID: 24651006
[TBL] [Abstract][Full Text] [Related]
14. WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation.
Esen E; Chen J; Karner CM; Okunade AL; Patterson BW; Long F
Cell Metab; 2013 May; 17(5):745-55. PubMed ID: 23623748
[TBL] [Abstract][Full Text] [Related]
15. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.
Masui K; Shibata N; Cavenee WK; Mischel PS
Bioessays; 2016 Sep; 38(9):839-44. PubMed ID: 27427440
[TBL] [Abstract][Full Text] [Related]
16. Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1).
Liu B; Huang ZB; Chen X; See YX; Chen ZK; Yao HK
Cell Mol Neurobiol; 2019 Apr; 39(3):415-434. PubMed ID: 30771196
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance.
Wang RH; Kim HS; Xiao C; Xu X; Gavrilova O; Deng CX
J Clin Invest; 2011 Nov; 121(11):4477-90. PubMed ID: 21965330
[TBL] [Abstract][Full Text] [Related]
18. Target of Rapamycin Complex 2 regulates cell growth via Myc in Drosophila.
Kuo Y; Huang H; Cai T; Wang T
Sci Rep; 2015 May; 5():10339. PubMed ID: 25999153
[TBL] [Abstract][Full Text] [Related]
19. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
[TBL] [Abstract][Full Text] [Related]
20. Mdm20 Modulates Actin Remodeling through the mTORC2 Pathway via Its Effect on Rictor Expression.
Yasuda K; Takahashi M; Mori N
PLoS One; 2015; 10(11):e0142943. PubMed ID: 26600389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
